Skip to main content

Table 7 Prognostic markers involved in other aspects of ESCC as reported in original studies

From: Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review

Marker

References

Sample size

Clinical stage

OS

DFS

Analytic methods

HR

95% CI

P value

HR

95% CI

P value

PKM2

Zhan et al. [17]

210

I–IV

1.748

1.277–2.395

<0.001

Cox proportional hazards model

Li et al. [24]

141

I–IV

1.214

0.728–2.026

0.458

Cox proportional hazards model

Zhang et al. [95]

86

I–IV

2.358

1.156–4.812

0.018

Cox proportional hazards model

Fukuda et al. [96]

205

I–IV

1.850

1.200–2.780

0.0189

Cox proportional hazards model

CXCR4

Gockel et al. [25]

53

I–III

1.472

0.836–2.593

0.181

Cox proportional hazards model

Zhang et al. [98]

136

I–IV

1.612

1.072–2.425

0.022

1.708

1.126–2.591

0.012

Cox proportional hazards model

Lu et al. [99]

127

I–III

1.720

0.749–3.928

0.202

1.497

0.659–3.399

0.335

Cox proportional hazards model

Qi et al. [100]

60

0.001

Log-rank test

Sasaki et al. [101]

214

I–IV

0.4

0.3

Log-rank test

MLH1

Tzao et al. [18]

60

I–IV

0.18

Log-rank test

Kishi et al. [104]

156

I–IV

2.020

1.146–4.231

0.018

Cox proportional hazards model

Uehara et al. [105]

122

I–IV

0.0043

Log-rank test

  1. ESCC esophageal squamous cell carcinoma, PKM2 pyruvate kinase M2, CXCR4 C-X-C chemokine receptor type 4, MLH1 mut-L-homologon-1, OS overall survival, DFS disease-free survival, HR hazard ratio, CI confidence interval, no data